News Releases

ATLANTA , Dec. 9, 2024 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis

Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.3) million or ( $0.05 ) per fully diluted share and non-GAAP

ATLANTA , Nov. 5, 2024 /PRNewswire/ --  Artivion, Inc.   (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Stifel 2024

ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results will be released on Thursday, November 7, 2024 after the market closes.

5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfusion Resolution in 90% of Affected Subjects Post-AMDS Implantation 1-Year Data from the NEOS Study

Second Quarter Highlights:  Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency basis Net loss was ($2.1) million or ( $0.05 ) per fully diluted share and non-GAAP net income was

ATLANTA , Aug. 5, 2024 /PRNewswire/ --   Artivion, Inc.   (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Canaccord

ATLANTA , July 25, 2024 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes.

Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million , inclusive of loan off-set, and $100 million earnout minimum eliminated  ATLANTA , July 1, 2024 /PRNewswire/ -- Artivion, Inc.

First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $7.5 million or $0.18 per fully diluted share and non-GAAP net